1786 — Scivision Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapHigh Flyer

Annual income statement for Scivision Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	467	506	557	713	883
Cost of Revenue
Gross Profit	343	342	372	512	656
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	320	384	423	513	635
Operating Profit	147	122	135	200	248
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	152	116	174	210	292
Provision for Income Taxes
Net Income After Taxes	128	102	142	178	242
Net Income Before Extraordinary Items
Net Income	128	102	142	178	242
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	133	107	144	184	246
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.04	1.51	1.59	2.4	3.3
Dividends per Share